HTDS announces closure of Regulation D 504 offering

Sep 4 2009

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors. A Form D will be filed with the Securities and Exchange Commission shortly, disclosing that the company has raised $990,000 in the offering over the past twelve months. The limit to any such offering is $1 million per year.

HTDS is a holding company for China-based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of biological vaccines in China. Based on the cooperation with Institutes of Medical Biology and pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy. HTDS' other controlling interests include an East European (Serbian) medical company, Slavica Biochem, whose experts are performing cutting edge research in the field of neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI). The primary focus of Slavica Biochem is to investigate novel therapeutic approaches in treatment of these disorders of the CNS (central nervous system), as well as to enhance and modify existing approved drugs such as VIRAZOLE(R).

Closing the 504 offering brings to an end the issuer's recent use of equity in financing operations. With the new increased pool of credit the issuer intends to cover a majority of its upfront costs associated with its increasing contract demands. The issuer is looking forward to releasing quite a bit of new information over the next few weeks, including the finalized contracts as well as outlining its revised business plan to shareholders and potential investors. The revised business plan under consideration includes an anti-aging and cancer treatment project through nutritional supplementation.

The equity in financing has also opened up an opportunity for HTDS management to explore a possible lucrative joint venture project with a North American-based pharmaceutical company.

The issuer does not foresee the need or reason to disturb its current share structure, through dilution or otherwise. Management now intends to recalibrate its focus to its previously announced plans of addressing its share price, and matters that will increase its shareholder value. The issuer remains very optimistic that a 0.03 cent price per share is within its reach.

The issuer intends to furnish its shareholders with forward guidance shortly.